Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 12, Number 1—January 2006


Coordinated Response to SARS, Vancouver, Canada

Danuta M. Skowronski*Comments to Author , Martin Petric*, Patricia Daly†, Robert A. Parker‡, Elizabeth Bryce†, Patrick W. Doyle†, Michael A. Noble†, Diane L. Roscoe†, Joan Tomblin§, Tung C. Yang¶, Mel Krajden*, David M. Patrick*, Babak Pourbohloul*, Swee Han Goh*, William R. Bowie#, Tim F. Booth**, S. Aleina Tweed*, Thomas L. Perry†, Allison McGeer††, and Robert C. Brunham*
Author affiliations: *British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada; †Vancouver Coastal Health, Vancouver, British Columbia, Canada; ‡Fraser Health, New Westminster, British Columbia, Canada; §Royal Columbian Hospital, New Westminster, British Columbia, Canada; ¶St. Paul's Hospital, Vancouver, British Columbia, Canada; #University of British Columbia, Vancouver, British Columbia, Canada; **National Microbiology Laboratory, Winnipeg, Manitoba, Canada; ††Mount Sinai Hospital, Toronto, Ontario, Canada

Main Article

Table 1

SARS CoV antibody titers by microneutralization assay in persons with laboratory-confirmed SARS in VCMA*

Serum sample no. Patient 0
Patient 1
Patient 2
Patient 3
Patient 4
Days after onset Titer Days after onset Titer Days after onset Titer Days after onset Titer Days after onset Titer
1 10 1:32 16 1:128 4 <1:8 3 <1:8 11 <1:8
2 19 1:128 29 1:32 14 1:32 36 1:128 28 1:32
3 45 1:32 637 1:64 20 1:128 224 1:128 203 1:128
4         217 1:128 466 1:64 463 1:64
5         481 1:64        

*By number of days after symptom onset that serum was collected. SARS, severe acute respiratory syndrome; CoV, coronavirus; VCMA, Vancouver census metropolitan area.

Main Article